Pirfenidone Prevents Heart Fibrosis during Chronic Chagas Disease Cardiomyopathy
International Journal of Molecular Sciences · 03.07.2024 · 25 (13) · 7302
DOI: 10.3390/ijms25137302 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.07.2024. Verfasst von Tatiana Araújo Silva und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Ultrastructure Laboratory, Oswaldo Cruz Institute (IOC), FIOCRUZ, Rio de Janeiro 21040-360, RJ, Brazil. Hauptthemen laut MEDLINE: Pyridones, Chagas Cardiomyopathy, Fibrosis, Mice, Inbred C57BL. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, University of California, San Diego, Academic Senate Health Sciences Research Grant, University of California San Diego.
Abstract (Originalsprache)
Cardiac fibrosis is a severe outcome of Chagas disease (CD), caused by the protozoan Trypanosoma cruzi. Clinical evidence revealed a correlation between fibrosis levels with impaired cardiac performance in CD patients. Therefore, we sought to analyze the effect of inhibitors of TGF-β (pirfenidone), p38-MAPK (losmapimod) and c-Jun (SP600125) on the modulation of collagen deposition in cardiac fibroblasts (CF) and in vivo models of T. cruzi chronic infection. Sirius Red/Fast Green dye was used to quantify both collagen expression and total protein amount, assessing cytotoxicity. The compounds were also used to treat C57/Bl6 mice chronically infected with T. cruzi, Brazil strain. We identified an anti-fibrotic effect in vitro for pirfenidone (TGF-β inhibitor, IC50 114.3 μM), losmapimod (p38 inhibitor, IC50 17.6 μM) and SP600125 (c-Jun inhibitor, IC50 3.9 μM). This effect was independent of CF proliferation since these compounds do not affect T. cruzi-induced host cell multiplication as measured by BrdU incorporation. Assays of chronic infection of mice with T. cruzi have shown a reduction in heart collagen by pirfenidone. These results propose a novel approach to fibrosis therapy in CD, with the prospect of repurposing pirfenidone to prevent the onset of ECM accumulation in the hearts of the patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular Ultrastructure Laboratory, Oswaldo Cruz Institute (IOC), FIOCRUZ, Rio de Janeiro 21040-360, RJ, Brazil.
- Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
ORCID-Profile: Jair L Siqueira-Neto
Förderung
- NINDS NIH HHS
- University of California, San Diego
- Academic Senate Health Sciences Research Grant, University of California San Diego
- Programa de Doutorado Sanduíche no Exterior (PDSE) from CAPES, edital PDSE2016
Zitieren
APA
Silva, T. A., Thomas, D., Siqueira-Neto, J. L., & Calvet, C. M. (2024). Pirfenidone Prevents Heart Fibrosis during Chronic Chagas Disease Cardiomyopathy. International Journal of Molecular Sciences, 25(13), 7302. https://doi.org/10.3390/ijms25137302
Vancouver
Silva TA, Thomas D, Siqueira-Neto JL, Calvet CM. Pirfenidone Prevents Heart Fibrosis during Chronic Chagas Disease Cardiomyopathy. International Journal of Molecular Sciences. 2024;25(13):7302. doi:10.3390/ijms25137302
BibTeX
@article{Silva2024,
author = {Silva, Tatiana Araújo and Thomas, Diane and Siqueira-Neto, Jair L and Calvet, Claudia Magalhaes},
title = {Pirfenidone Prevents Heart Fibrosis during Chronic Chagas Disease Cardiomyopathy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {13},
pages = {7302},
doi = {10.3390/ijms25137302}
}
EUVIMED